DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 216 filers reported holding DENALI THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is 0.32 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $8,076,419 | -69.8% | 350,539 | -63.5% | 0.02% | -71.7% |
| Q4 2022 | $26,715,371 | +28.8% | 960,639 | +42.1% | 0.06% | +33.3% |
| Q3 2022 | $20,744,000 | -13.8% | 675,870 | -17.3% | 0.04% | -10.0% |
| Q2 2022 | $24,063,000 | +389.3% | 817,650 | +434.9% | 0.05% | +455.6% |
| Q1 2022 | $4,918,000 | -71.3% | 152,855 | -60.2% | 0.01% | -71.9% |
| Q4 2021 | $17,123,000 | -36.1% | 383,944 | -27.7% | 0.03% | -71.2% |
| Q3 2021 | $26,808,000 | -47.1% | 531,358 | -17.7% | 0.11% | -51.5% |
| Q2 2021 | $50,672,000 | +791.8% | 645,999 | +549.1% | 0.23% | +780.8% |
| Q1 2021 | $5,682,000 | -51.2% | 99,518 | -69.4% | 0.03% | -65.3% |
| Q3 2020 | $11,651,000 | +1148.8% | 325,168 | +743.1% | 0.08% | +971.4% |
| Q2 2020 | $933,000 | -78.0% | 38,570 | -84.1% | 0.01% | -83.3% |
| Q1 2020 | $4,239,000 | +424.6% | 242,120 | +422.1% | 0.04% | +600.0% |
| Q4 2019 | $808,000 | +12.5% | 46,377 | +49.9% | 0.01% | +100.0% |
| Q1 2019 | $718,000 | – | 30,946 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 7,460,732 | $240,012,000 | 28.78% |
| Casdin Capital, LLC | 1,500,000 | $48,255,000 | 2.16% |
| Flagship Pioneering Inc. | 2,619,968 | $84,284,000 | 1.98% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 38,000 | $8,192,000 | 1.85% |
| Yiheng Capital Management, L.P. | 1,014,684 | $32,642,000 | 1.49% |
| SECTORAL ASSET MANAGEMENT INC | 207,100 | $6,662,000 | 1.18% |
| Artal Group S.A. | 600,000 | $19,302,000 | 0.81% |
| GILDER GAGNON HOWE & CO LLC | 2,619,217 | $84,260,000 | 0.78% |
| Temasek Holdings (Private) Ltd | 5,369,487 | $172,736,397 | 0.73% |
| BRANDYWINE MANAGERS, LLC | 9,601 | $309,000 | 0.53% |